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Available online 25 July 2016Normal human brain development is dependent on highly dynamic epigenetic processes for spatial and temporal
gene regulation. Recent work identiﬁed wide-spread changes in DNA methylation during fetal brain develop-
ment. We proﬁled CpG methylation in frontal cortex of 27 fetuses from gestational weeks 12–42, using Illumina
450K methylation arrays. Sites showing genome-wide signiﬁcant correlation with gestational age were
compared to a publicly available data set from gestational weeks 3–26. Altogether, we identiﬁed 2016 matching
developmentally regulated differentially methylated positions (m-dDMPs): 1767 m-dDMPs were
hypermethylated and 1149 hypomethylated during fetal development. M-dDMPs are underrepresented in
CpG islands and gene promoters, and enriched in gene bodies. They appear to cluster in certain chromosome
regions. M-dDMPs are signiﬁcantly enriched in autism-associated genes and CpGs. Our results promote the
idea that reduced methylation dynamics during fetal brain development may predispose to autism. In addition,
m-dDMPs are enriched in genes with human-speciﬁc brain expression patterns and/or histone modiﬁcations.
Collectively, we deﬁned a subset of dDMPs exhibiting constantmethylation changes fromearly to late pregnancy.
The same epigenetic mechanisms involving methylation changes in cis-regulatory regions may have been
adopted for human brain evolution and ontogeny.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Methylome1. Introduction
The complexity of the human brain and cognitive functions is
interrelated with temporally and spatially highly coordinated gene regu-
lation during fetal brain development. Recent studies have elucidated the
underlying epigeneticmechanisms, in particular the neurodevelopmental
trajectories in fetal brain DNA methylation (Numata et al., 2012; Pidsley
et al., 2014; Spiers et al., 2015; Jaffe et al., 2016) and gene transcription
(Colantuoni et al., 2011; Lambert et al., 2011; Miller et al., 2014; Jaffe
et al., 2015). Accumulating evidence suggests that DNA methylation in
human prefrontal cortex is highly dynamic during the ﬁrst and second
trimester, compared to the adult brain where most developmentally
dynamic genes display relatively small changes with age. Theserodmann area; CGI, CpG island;
ntally regulated differentially
n; m-dDMP, matching dDMP.
, Julius-Maximilians-Universität
ermany.
aaf).
. This is an open access article underdevelopmentally regulated differentially methylated positions in the
genome have been referred to as dDMPs (Spiers et al., 2015). CpG islands
(CGIs) are 500–2000 bp DNA segments with high CpG density that are
associated with most mammalian genes. Methylation of these cis-
regulatory regions during development or disease processes is associated
with posttranslational histone modiﬁcations that lead to a locally con-
densed inactive chromatin structure and gene silencing (Jaenisch and
Bird, 2003;Weber et al., 2007). In contrast, gene bodymethylation is pos-
itively correlated with transcription and may have functions in silencing
transposable elements and regulating splicing (Yoder et al., 1997;
Laurent et al., 2010; Jones, 2012). The epigenome is the sum of the epige-
neticmodiﬁcations in a cell type or tissuewhich bring the phenotype into
being. One important hallmark of the epigenome is its enormous plastic-
ity in response to internal (i.e. during development) and environmental
factors (Haaf, 2006; Feil and Fraga, 2012).
It is plausible to assume that genes associated with dDMPs play an
important role for brain development and that misregulation in
sensitive time windows may interfere with normal brain function.
Indeed, dDMPs were found to be enriched in genomic regions that
have been associated with schizophrenia and autism (Spiers et al.,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
111E. Schneider et al. / Gene 592 (2016) 110–1182015; Hannon et al., 2016). Both schizophrenia and autism have a high
heritability (up to 80%) and are thought to have a basis in
neurodevelopmental disturbances of the fetal brain (Fatemi and
Folsom, 2009; Werling and Geschwind, 2013). Schizophrenia is
characterized by abnormalities in the perception or expression of reali-
ty, affecting cognitive and psychomotor functions (http://www.
icd10data.com). Autism spectrum disorder (ASD) is characterized by
deﬁcits in social interactions, communicative impairments and stereo-
typic behavioral patterns (Zafeiriou et al., 2013). It is hypothesized
that the disease manifests when the sum of adverse genetic, epigenetic
and/or environmental factors exceeds a critical threshold (Loke et al.,
2015). In contrast to schizophrenia and autism, Alzheimer's disease is
a neurodegenerative disorder resulting from progressive dysfunction,
degeneration and death of neurons in the human brain. Epigenetic
modiﬁcations are altered during ageing and Alzheimer pathogenesis
(Lunnon and Mill, 2013; Levine et al., 2015).
Here we performed amethylation array analysis of fetal cortex sam-
ples to identify dDMPs and developmentally regulated genes. There are
already several studies (Numata et al., 2012; Pidsley et al., 2014; Spiers
et al., 2015; Jaffe et al., 2016) on the fetal brainmethylome, however due
to different techniques and tissue samples (brain region, gestational
week, spontaneous vs. elective abortion), existing data sets are likely
still polluted with false positives and false negatives. By comparing
our results with the most comprehensive study using Illumina 450 K
methylation arrays (Spiers et al., 2015), we deﬁned a subset of approx-
imately 3000 dDMPs showing signiﬁcant changes in the same direction
across fetal brain development.2. Materials and methods
2.1. Subjects and sample preparation
This study was approved by the ethics committees of the
Landesärztekammer Rheinland-Pfalz (no. 837.103.04_4261) and the
Medical Faculty of the University of Würzburg, Germany (no. 262/14).
Brain samples (Table 1) were obtained from excess material of fetalTable 1
Fetal frontal cortex samples.
Cortex sample Sex Gestational week Cause of death
1 F 12 Amniotic infection
2 F 13 Amniotic infection
3 M 15 Retroplacental hemorrhag
4 F 15 Premature placental abru
5 M 15 Chorioamnionitis with ne
6 F 17 Premature rupture of mem
7 F 17 Premature placental abru
8 M 18 Amniotic infection
9 F 18 Premature rupture of mem
10 M 18 Premature rupture of mem
11 M 18 Amniotic infection
12 M 19 Premature rupture of mem
13 F 20 Not known
14 F 20 Premature placental abru
15 M 20 Amniotic infection
16 M 20 Not known
17 F 20 Amniotic infection
18 M 21 Not known
19 M 21 Not known
20 F 22 Premature rupture of mem
21 F 23 Premature rupture of mem
22 F 23 Preterm labor
23 F 23 Preterm labor
24 M 24 Chorioamnionitis
25 M 25 Premature placental abru
26 F 32 Umbilical cord stricture
27 F 42 Placental insufﬁciencyautopsies. After determination of postmortem time (based on anamnes-
tic data and autolytic processes) and gestational age (foot length mea-
surements), cortex tissue was dissected from the frontal lobe (BA10).
Chromosome disorders were excluded by karyotype analyses of prima-
ry ﬁbroblast cultures from Achilles tendon.
Tissue samples were disrupted using the Precellys tissue DNA kit
(PEQLAB, Erlangen, Germany). Genomic DNA was isolated with the
DNeasy blood and tissue kit (Qiagen, Hilden, Germany). Bisulﬁte con-
version was performed using one microgram DNA and the EZ-96 DNA
methylation kit (Zymo Research, Irvine, CA, USA). Total RNA was
isolated with the RNeasy lipid and tissue mini kit (Qiagen). Amount
and quality of DNA and RNA were analyzed with an Agilent 2100
Bioanalyzer (Agilent, Santa Clara, CA, USA) system.2.2. Microarray analysis
After bisulﬁte conversion, the 27 samples were whole-genome am-
pliﬁed, enzymatically fragmented, and hybridized to two Illumina
HumanMethylation450 (450K) BeadChips according to the
manufacturer's protocol (Illumina, San Diego, CA, USA). The arrays
were scannedwith an Illumina iScan.Microarray data (NCBI GEO acces-
sion no. GSE73747) were exported as idat ﬁles and preprocessed using
the RnBeads pipeline with default settings (Assenov et al., 2014). 4713
sites overlapping SNPs, 3156 sites not in the CpG context and 523
probes ﬂagged as unreliable based on the corresponding detection P
value were removed. Furthermore, 11,169 probes on the sex chromo-
somes were excluded, leaving a total number of 465,572 probes
(covering 99% of RefSeq genes with promoter, ﬁrst exon, gene body, 5′
and 3′UTRs and 96% of CpG islands) for subsequent analyses. The signal
intensity values were normalized using the SWANnormalizationmeth-
od (Maksimovic et al., 2012), as implemented in the minﬁ package
(Aryee et al., 2014). Differential methylation analysis has been per-
formed using the moderated t-test model as implemented in the
limma package (Ritchie et al., 2015) based on β values of the fetal sam-
ples. CpG sites exhibiting a linear correlation N0.7 (FDR adjusted
P b 0.05) with gestational age (weeks) were considered as dDMPs.Abortion Postmortem time (h)
Induced 36
Spontaneous 24–48
e Spontaneous 48–72
ption Spontaneous 24–48
crosis Spontaneous 24–48
branes Induced b24
ption Induced b24
Spontaneous b24
branes and amniotic infection Spontaneous 24–48
branes Induced b24
Spontaneous b24
branes and chorioamnionitis Spontaneous 24–48
Induced b24
ption Spontaneous b24
Spontaneous b24
Induced 24–48
Induced b24
Induced b24
Spontaneous 72
branes Spontaneous 24–48
branes and chrorioamnionits Spontaneous 24–48
Spontaneous 48
Spontaneous 48
Spontaneous 72
ptio Spontaneous 24–48
Spontaneous 48
Spontaneous b24
Fig. 1. The upper panel shows the distribution of dDMPs in the linear genome (x-axis).
CpG islands are ﬂanked by shores (up to 2 kb) and shelves (2–4 kb from CGI). The open
sea represent the rest of the genome. Gray bars represent the percentage of dDMPs and
white bars the percentage of assessed CpG sites in a speciﬁc region. CpG islands are
signiﬁcantly (P b 0.01) depleted of dDMPs. The lower panel shows the ratio of
hypermethylated dDMPs (gray bars) versus hypomethylated dDMPs (white bars) in
different genomic regions.
Table 2
Comparison of this study with a published data set.
Spiers et al., 2015 This study Matching dDMPs
Analyzed tissue Brain Frontal cortex
Number of samples 179 27
Sex 100♂, 79 ♀ 12♂, 15 ♀
Gestational weeks 3–26 12–42
Number of analyzed probes 408,608 464,616
Number of dDMPs 28,718 36,261 6344
Hypomethylated dDMPs 16,190 11,794 1149
Hypermethylated dDMPs 12,528 24,467 1767
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A customized TruSeq RNAexpression panel (IlluminaDesign Studio)
with 25 assays (El Hajj et al., 2016) targeted DNMT3B, NRSF/REST and
four internal control genes (as well as several other genes without m-
dDMPs). All RNA samples were analyzed in technical duplicates.
cDNAs were synthesized from 20 fetal frontal cortices using ProtoScript
II Reverse Transcriptase (NEB, Frankfurt/Main, Germany). Subsequent
stepswere performed according to the TruSeq targeted RNA expression
guide. The resulting TruSeq RNA librarywas sequenced for 50 cycles and
dual-index 6 and 8 cycles using a IlluminaMiSeq and theMiSeq Reagent
Kit v3. Mapping and counting were performed with Illumina
GenomeStudio software. Differential expression analysis was per-
formed using the limma modeling framework (Ritchie et al., 2015) in
combination with the “voom” method (Law et al., 2014) which has
been speciﬁcally designed for the analysis of count data in RNASeq
experiments.
2.4. Bioinformatic analysis
We compared the lists of signiﬁcant dDMPs in our and a conceptually
related study (Spiers et al., 2015). Only matching m-dDMPs which
showed signiﬁcant correlation with gestational age and the same direc-
tion of change (up- or downmethylation) in both data sets were consid-
ered for further analysis. To study their chromosomal distribution, the
number of hypo- and hypermethylated dDMPs, respectively, on each
chromosome was determined and compared to the number of 450K
array probes on the respective chromosome. Subsequently, all CpG sites
assessed by the array were aggregated into positional clusters with 5 or
more sites. These positional clusters were then used for local enrichment
analysis of m-dDMPs. Enrichment or depletion were calculated using
Fisher's exact test with Bonferroni correction for multiple testing
(P b 0.05). Genes associatedwithm-dDMPswere compared to candidate
gene lists for autism (Autism database AutDB, 2015; http://autism.
mindspec.org/autdb; Basu et al., 2009), schizophrenia (Schizophrenia
Working Group of the Psychiatric Genomics Consortium, 2014), and
Alzheimer's disease (AlzGene database, 2015; http://www.alzgene.org;
Bertram et al., 2007).
A literature search identiﬁed genes with possible human-speciﬁc
regulation in the adult primate brain (Supplementary Table S1). Alto-
gether, we selected 2357 protein-coding genes (Nowick et al., 2009;
Liu et al., 2012; Florio et al., 2015) and 153 microRNAs (Hu et al.,
2011) with human-speciﬁc brain expression patterns, and 441 genes
with human-speciﬁc histone methylation signatures at transcription
start sites (Shulha et al., 2012).
3. Results
3.1. Methylation array analysis
Frontal cortex samples of 12 male and 15 female fetuses ranging
from gestational weeks 12 to 42 (Table 1) were hybridized on Inﬁnium
HumanMethylation450 BeadChips. Altogether, 36,261 (7.8%) of
465,572 assessed CpG sites (excluding sex chromosomes) showed
signiﬁcant (adjusted P b 0.05, R N 0.7) methylation changes with gesta-
tional age. Localization of these dDMPs in the genome was classiﬁed
into different categories: CpG islands, ﬂanking CGI shores and shelves,
and open sea (Fig. 1). Shores are regions up to 2 kb and shelves 2–
4 kb from CGIs. The open sea represents CpGs not associated with an
CGI. dDMPs were signiﬁcantly (Fisher's exact test, P b 0.01 depleted in
CpG islands (Fig. 1, upper panel). The majority, namely 24,467 (67.5%)
dDMPs gainedmethylation and 11,794 (32.5%) lost methylation during
intrauterine development. Although hypermethylated dDMPs were
more frequent in all genomic regions (Fig. 1, lower panel), themost dra-
matic abundance was observed in CpG islands, where 95% of dDMPs
were hypermethylated.Approximately 36,000 dDMPs were identiﬁed in our data set, com-
pared to 29,000 in an earliermethylation array study on fetal brain sam-
ples (Spiers et al., 2015). It is noteworthy that in our study the majority
(67.5%) of dDMPs were hypermethylated, whereas in the published
data set hypomethylated dDMPs (56.4%) predominated (Table 2). Of
6344 dDMPs which were signiﬁcant in both data sets, more than half
showed methylation changes in opposite direction. This leaves us with
1767 hypermethylated and 1149 hypomethylated dDMPs, matching
between both studies (Fig. 2, upper panel). These 2916 matching m-
dDMPs are continuously gaining or loosing methylation from early to
late gestational stages. When focusing on genes, 684 were associated
with hypermethylated, 733 with hypomethylated, and 62 with both
hyper- and hypomethylated m-dDMPs (in different regions of the
gene). 216 m-dDMPs were mapped to 105 promoter regions (1.5 kb
upstream to 0.5 kb downstream of transcriptions start sites),
representing 74 hyper- and 31 hypomethylated m-dDMP promoters.
Fig. 2.Methylation trajectories of m-dDMPs and o-dDMPs. Blue dots represent fetal brain samples from a published data set (Spiers et al., 2015), red dots fetal cortex samples from our
study. The x axis represents the gestational age in weeks and the y axis the methylation beta value. Regression lines are calculated for blue (median gestational age 13 weeks) and red
samples (20 weeks), respectively. The upper panel demonstrates representative examples of m-dDMPs which exhibit signiﬁcant methylation changes in the same direction in both
studies. The bottom panel shows representative examples of o-dDMPs which exhibit signiﬁcant methylation changes in opposite directions.
113E. Schneider et al. / Gene 592 (2016) 110–118The majority of genic dDMPs were located in gene bodies, which are
signiﬁcantly enriched with dDMPs (Fig. 3, upper panel). The region up-
streamof the transcription start site (TSS1500 and TSS200) and the ﬁrst
exon were signiﬁcantly depleted of dDMPs. With exception of UTRs, in
particular the 3′ UTR (with N60% hypomethylated dDMPs), the
hypermethylated dDMPs predominated (Fig. 3, lower panel).
Another recent 450K array study (Mendioroz et al., 2015) focussing
on methylation changes in Down syndrome (DS) showed dynamic
methylation changes in fetal cerebrum (of 8 DS and 6 control samples).
Following adjustment for DS status, 5775 developmentally regulated
CpG sites were identiﬁed, including 657 of our 2916 m-dDMPs. Thisoverlap is highly signiﬁcant (P b 0.0001) and moreover the direction
of change for all overlapping (262 hyper- and 395 hypomethylated)
m-dDMPs was identical in both studies. This indicates that the
identiﬁed m-dDMPs are robust, reﬂecting developmental trajectories
of the whole brain.
To determine whether the observed developmental methylation
changes affect gene expression, targeted RNA sequencing was per-
formed for two key regulatory genes with hypermethylated m-dDMPs
promoters, namely the de novo methyltransferase DNMT3B and the
neuron-restrictive silencer factor/RE1-silencing transcription factor
NRSF/REST. Consistent with their increasing methylation, both genes
Fig. 3. The upper panel shows the distribution of dDMPs in different gene regions. TSS200
is the region from transcription start site (TSS) to −200 bp, TSS1500 from −200 bp
to−1500 bp upstream of TSS. Gray bars represent the percentage of dDMPs and light
bars the percentage of assessed CpG sites in a speciﬁc region. Gene promoters (TSS1500,
TSS200 and 1st exon) are signiﬁcantly (P b 0.01) depleted of and gene bodies enriched
with dDMPs. The lower panel shows the ratio of hypermethylated (gray bars) versus
hypomethylated dDMPs (light bars) in different gene regions.
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ment (Fig. 4). Since signiﬁcant expression changeswere seen in two dif-
ferent assays each, artifacts can be largely excluded.
The large (3428 of 6344) number of dDMPs with genome-wide
signiﬁcance in both studies but opposite direction of change does not
necessarily reﬂect experimental artifacts. Different developmental
time windows may account for a substantial fraction of these opposing
dDMPs (o-dDMPs). Gestational age was signiﬁcantly lower in the pub-
lished data set (Spiers et al., 2015) than in our study (Table 2). When
plotting methylation versus gestational age for o-dDMPs, 2971 show a
U-shaped methylation dynamics, being downmethylated in the ﬁrst
and upmethylated in the second trimester (Fig. 2, lower panel). A small-
er number of 457 o-dDMPs displayed a reverse U shape, being
upmethylated in the ﬁrst and downmethylated in the second trimester.
This is consistent with the abundance of hypomethylated dDMPs in the
published data set (Spiers et al., 2015) and of hypermethylated dDMPs
in our study. The turningpoint formost o-dDMPswas around gestation-
al week 15.
3.2. Chromosomal distribution and clustering of m-dDMPs
Fig. 5 shows the chromosomal distribution of hyper- and
hypomethylated dDMPs. Compared to the number of analyzed CpGs
on the array, chromosomes 1 and 10 are signiﬁcantly (adjusted
P b 0.05) enriched with hypermethylated and chromosome 22 with
hypomethylated dDMPs. Chromosome 19 is signiﬁcantly depleted of
hypermethylated dDMPs. To test whether dDMPs are stochastically dis-
tributed or clustered in certain chromosome region, we ﬁrst deﬁned
clusters containing 5 or more adjacent CpG sites on the array. Based
on the array architecture, we identiﬁed 24,588 such CpG clusters,covering a total of 231,788 CpGs (28.9% of all analyzed sites). To detect
local enrichment of m-dDMPs mapping to these positional clusters,
Fisher's exact test was calculated for each cluster separately. After mul-
tiple testing correction, 68 clusters showed a signiﬁcant (adjusted
P b 0.05) enrichment with m-dDMPs. Genomic coordinates of these
clusters and the correlation between regional methylation and gesta-
tional age are presented in Supplementary Table S2. Most (88%) m-
dDMP clusters are located in coding sequence, howeverwhen consider-
ing that most CpGs on the array interrogate gene regions, this is not a
signiﬁcant enrichment (Fisher's exact test). For visualization, the
280 m-dDMPs were plotted along the length of chromosomes (Fig. 6).
It is noteworthy that all chromosomes apart from 9, 13, 18, and 21 are
endowed with m-dDMP clusters.
3.3. Association of dDMPs with autism
Approximately half (1477 of 2913) of m-dDMPs are associated with
genes. To testwhetherm-dDMPs are enriched in genes for neuropsychi-
atric disorders, we used published lists of 742 genes that have been
associated with ASD (AutDB, 2015; Basu et al., 2009), 119 genes associ-
ated with schizophrenia (Schizophrenia Working Group of the
Psychiatric Genomics Consortium, 2014), and 678 genes associated
with Alzheimer's disease (AlzGene, 2015; Bertram et al., 2007). The
only candidate gene set showing signiﬁcant (P b 0.0001) enrichment
with m-dDMP genes (96 of 742) was autism: 50 ASD candidate genes
were associated with hypermethylated, 41 with hypomethylated, and
5 with both hypo- and hypermethylated m-dDMPs. A recent 450K
methylation array study (Nardone et al., 2014) identiﬁed 5329 CpG
sites with signiﬁcant methylation changes in adult frontal cortex
(BA10) of autistic patients, compared to controls. There is a highly
signiﬁcant (N = 83; P b 0.0001) overlap between CpGs that are
differentially methylated in adult autistic frontal cortex (5329) and
our m-dDMP marker set (2916). Even more interestingly, 7 of 8
hypomethylated m-dDMPs showed higher methylation and 70 of 75
hypermethylated m-dDMPs decreased methylation in the adult autistic
brain. Another 450K array study (Ladd-Acosta et al., 2014) revealed
three differentially methylated regions (with 74 CpG sites on the
array) in adult temporal cortex of 19 autism cases versus 21 controls.
One DMR with decreased methylation in the adult autistic brain was
associated with PPRT1, which represents a hypermethylated m-dDMP
gene in our study. This leads to a model that incomplete
downmethylation and upmethylation, respectively, of m-dDMPs during
fetal development persist into the adult brain and predisposes to autism
(Fig. 7).
Recent work using 450K methylation arrays identiﬁed 2104 differ-
entially methylated, mainly hypomethylated CpGs in adult frontal cor-
tex from patients with schizophrenia (Jaffe et al., 2016). However,
only one of these 2104 CpGs, cg16884940 in the CCDC53 gene body, co-
incided with a m-dDMP in our study. Unlike autism, schizophrenia-
associated CpGs (in adult brain) appear to be signiﬁcantly (P b 0.0001)
underrepresented in m-dDMPs.
3.4. M-dDMPs and human-speciﬁc changes in gene regulation during
primate brain evolution
We deﬁned a list (Supplementary Table S1) of 2357 protein-coding
genes with human-speciﬁc brain expression patterns (Nowick et al.,
2009; Liu et al., 2012; Florio et al., 2015) and 441 genes close to
human-speciﬁc histone methylation signatures (Shulha et al., 2012).
These genes which acquired human-speciﬁc regulation during brain
evolution are signiﬁcantly enriched with m-dDMP genes (N = 255;
P b 0.0001). Because the functional relationship between DNAmethyla-
tion and transcription is mostwell established for promoter regions, we
concentrated further on geneswithm-dDMPs in the promoters regions,
exhibiting human-speciﬁc brain regulation. Eight of 2357 protein-
coding genes, namely AMOTL2, FAM19A5, IFIT2, IGFBP6, LARP1, MYO16,
Fig. 4.Methylation and expression changes of DNMT3B (upper panel) and NRSF/REST (bottom panel) in the developing brain. Methylation was measured by Illumina 450K arrays and
expression by targeted RNA sequencing. Each dot represents a fetal cortex sample. For methylation analysis, red and blue dots represent two m-dDMPs (cg22605822 and cg14224313)
in DNMT3B, purple and green dots two m-dDMPs (cg25313468 and cg24291500) in NRSF/REST. Regression lines are calculated for each m-dDMP separately. For expression analysis,
red and blue dots represent assays DNMT3B_6699965 and DNMT3B_6699954, respectively, purple and green dots REST_6968017 and REST_6715088, respectively.
115E. Schneider et al. / Gene 592 (2016) 110–118OPCML, and PHLDB1, and 6 of 441 genes, AMOTL2, GPRIN2, MUC5B,
NFAM1, OPCML, and TMEM72, with human-speciﬁc histone modiﬁca-
tions are endowed with m-dDMP promoters. In addition, microRNAs
which are differentially expressed in the human and primate brain
(Hu et al., 2011) are signiﬁcantly (P b 0.0001) enriched with m-dDMP
promoters. Six of 153, MIR219-2, MIR30A, MIR589, MIR1237, MIR193B,
and MIRLET7C are controlled by m-dDMP promoters. Altogether, 13 of
18m-dDMP promoters becomemethylated, suggesting that the respec-
tive genes (AMOTL2, FAM19A5, GRIN2, NFAM1, IGFBP6, LARP1, MYO16,
PHLDB1, and TMEM72) and miRNAs (MIR30A,MIR193B, MIR219-2, and
MIR1237) are downregulated towards the end of pregnancy. Three
genes (IFIT2, MUC5B, and OPCML) and two microRNAs (MIR589 and
MIRLET7C) become demethylated and likely activated during human
fetal brain development.
4. Discussion
The mechanisms underlying human brain evolution and ontogeny
are still far from being understood. In many respects, including size,
speed of growth, gyriﬁcation and energy consumption, in particular
during development, the human brain is outstanding (Vannucci and
Vannucci, 2000; Ulijaszek, 2002; Sakai et al., 2012; Lewitus et al.,
2013). Because the genetic differences between humans and chimpan-
zees are rather small (Varki and Altheide, 2005), it is plausible to as-
sume that enhanced encephalization and cognitive abilities of the
human brain are at least to some extent due to changes in gene regula-
tion. The same epigenetic mechanisms which have been adapted for
human brain evolution may also play a crucial role for ontogeny. Con-
sidering that epigenetic variation is much (at least one order of magni-
tude) higher than genetic variation (Bennett-Baker et al., 2003) and can
be inﬂuenced by environmental factors (Feil and Fraga, 2012; El Hajjet al., 2014), it may account for a large part of phenotypic variation. Ac-
cumulating evidence suggests that the methylome is highly dynamic
during human brain development (Numata et al., 2012; Pidsley et al.,
2014; Spiers et al., 2015; Jaffe et al., 2016). Disturbances in this orches-
trated process can be expected to interfere with normal brain develop-
ment and function.
One important goal of our study was to identify methylationmarkers,
in particular in genes and promoter regions, that are continuously up- or
downmethylated during fetal brain development. To this end, we com-
pared our results to a conceptually related 450K methylation array
study (Spiers et al., 2015) and only 2916 m-dDMPs with genome-wide
signiﬁcance and the same direction of change in both data sets were con-
sidered further. Because of legal and ethical restrictions (which differ be-
tween countries), there is only limited access to fetal brain samples and
tissue quality is often not optimum. One limitation of our study is the rel-
atively small sample size (N=27). Most of our brain samples were from
spontaneous or induced abortions due to amniotic infection or placental
problems. Although we cannot exclude that the various pathologies and
postmortem times (b24 h to 72 h) affect methylation patterns in individ-
ual samples, this does not explain the observed developmental trajecto-
ries. One advantage of our study is that all fetuses underwent autopsy
by an experienced pediatric pathologist and frontal cortex tissue was dis-
sected from a well-deﬁned area (BA10), compared to published data on
undissected brain tissue from different regions. In our experience, neuro-
nal cells andnon-neuronal cells cannot be reliably sorted from frozen fetal
cortex using NeuN-speciﬁc antibodies, because they are not always im-
munostaining positive. One important difference between the two stud-
ies, which may account for the large number of o-dDMPs, is gestational
age. The median age in our study was 20 gestational weeks (range 12–
42), whereas in the published data set it was 13 weeks (range 3–26).
The identiﬁed 1767 hypermethylated and 1149 hypomethylated m-
Fig. 5. Chromosomal distribution of hyper- and hypomethylated dDMPs, respectively.
Gray bars represent the percentage of analyzed CpGs on a particular chromosome, white
bars the percentage of hypermethylated (upper panel) versus hypomethylated (lower
panel) dDMPs. Chromosomes 1 and 10 are signiﬁcantly (adjusted P b 0.05) enriched
with and chromosome 19 is depleted of hypermethylated dDMPs. Chromosome 22 is
signiﬁcantly enriched with hypomethylated dDMPs.
Fig. 7. Disturbances in methylation dynamics during fetal development, leading to
increased methylation of hypomethylated m-dDMPs and decreased methylation of
hypermethylated m-dDMPs in the autistic brain.
116 E. Schneider et al. / Gene 592 (2016) 110–118dDMPs matching between both studies are developmental trajectories
continuously gaining and loosing methylation, respectively, from early
to late stages of pregnancy.Fig. 6. 68 chromosomal regions are enriched with 280 m-dDMPs. Hypomethylated m-dDMPs
chromosomal ideograms. Shading indicates correlation between m-dDMP methylation and ge
0.70 to 0.96, respectively.Several recent publications have linked dDMPs to
neurodevelopmental disorders, in particular autism and schizophrenia
(Pidsley et al., 2014; Spiers et al., 2015; Hannon et al., 2016). We have
tested candidate gene sets for neurodevelopmental and neurodegenera-
tive disorders for enrichment with m-dDMPs. Consistent with earlierare depicted as dots on the left side, hypermethylated m-dDMPs on the right side of the
stational age. Correlation coefﬁcients range from−0.70 (light) to−0.91 (dark) and from
117E. Schneider et al. / Gene 592 (2016) 110–118studies,m-dDMPswere enriched in genes that have been associatedwith
autism.M-dDMPs in autism genes signiﬁcantly overlappedwith differen-
tially methylated CpGs in the brain of adult autistic individuals
(Ladd-Acosta et al., 2014; Nardone et al., 2014). Our observation that
hypermethylated m-dDMPs are associated with hypomethylated regions
in the adult autistic brain and vice versa suggests that reduced methyla-
tion dynamics during fetal brain development leads to persistent changes,
which thenmay predispose to autism. Unlike autism, candidate genes for
schizophrenia (Schizophrenia Working Group of the Psychiatric
Genomics Consortium, 2014) and schizophrenia-associated CpGs (Jaffe
et al., 2016) did not show signiﬁcant enrichment with m-dDMPs.
Genes and microRNAs with dynamic promoter methylation during
fetal brain development are prime candidates for human brain evolution.
Among105m-dDMPpromoters,we identiﬁed12 genes and6microRNAs
with human-speciﬁc regulation in the human compared to primate
brains. Most of these promoters become methylated during human fetal
brain development, consistent with transcriptional downregulation. The
affected genes are involved in embryogenesis (LARP1), stem cell differen-
tiation and proliferation (NFAM1 and TMEM72), cell migration during de-
velopment (PHLDB1), neurite growth (GRIN2), synaptic maturation
(AMOTL2), and nervous system development (MIR30A, IGFBP6, MYO16).
One disadvantage of methylation array studies is that probes repre-
sent only 2%of all CpGs and arenot equally distributed throughout the ge-
nome.Most probes are targeted across genes (promoter, 5′UTR, 1st exon,
gene body, and 3′ UTR) and CpG islands (including ﬂanking CGI shores
and shelves). However, even when correcting for the unequal coverage
of interrogated CpGs across the linear genome, m-dDMPs appeared to
cluster in particular chromosome regions. This supports the notion that
developmental regulation (by DNA methylation) occurs not only at the
individual gene level but also in larger chromosomal domains. The linear
chromosomes are segmented into hundreds of topological domains and
subdomains, ensuring coordinated gene expression (Bickmore and van
Steensel, 2013). Some chromosomes (1, 10, and 22) were enriched with
and others (19) depleted of m-dDMPs. Chromosomes 9, 13, 18, and 21
did not contain any m-dDMP clusters. In the case of 13, 18, and 21 this
may be partially explained by their low gene content. Assuming that m-
dDMP clusters play an important role in fetal brain development, the
lack of such clusters may contribute to the viability of trisomies 13, 18,
and 21 after birth.
5. Conclusions
Collectively, our results support the view that DNA methylation
patterns are highly dynamic during human fetal brain (frontal cortex)
development. During the ﬁrst trimester the fetal brain is globally
hypomethylated, whereas in the second and third trimester
methylation increases. The identiﬁed 1767 hypermethylated and 1149
hypomethylated m-dDMPs are developmental trajectories continuous-
ly gaining and loosing methylation, respectively, from early to late
stages of pregnancy. We propose that these m-dDMPs have been
adopted for both brain evolution and ontogeny.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.gene.2016.07.058.
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